Austar Lifesciences Limited provided earnings guidance for the year ended December 31, 2020. For the year, the company expects to record a profit attributable to the owners of the company in the range of RMB 30 million to RMB 40 million for the year ended December 31, 2020, as compared to approximately RMB 8.1 million a year ago. The final result is subject to potential adjustments that might be recognized before finalization of the consolidated financial results for the year ended December 31, 2020. The board attributes such expected increase in profit principally to the significant growth of revenue and gross profit being recognized for the year ended 31 December 2020, which was mainly attributable to the higher level of backlog as at December 31, 2019 and the increase in the amount of order-in-take of the Group for the year ended December 31, 2020.